164 related articles for article (PubMed ID: 14564482)
1. Identification of new MHC-restriction elements for presentation of the p210(BCR-ABL) fusion region to human cytotoxic T lymphocytes.
Sun JY; Senitzer D; Forman SJ; Chatterjee S; Wong KK
Cancer Immunol Immunother; 2003 Dec; 52(12):761-70. PubMed ID: 14564482
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro.
Sun JY; Krouse RS; Forman SJ; Senitzer D; Sniecinski I; Chatterjee S; Wong KK
Cancer Res; 2002 Jun; 62(11):3175-83. PubMed ID: 12036931
[TBL] [Abstract][Full Text] [Related]
3. CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner.
Yasukawa M; Ohminami H; Kaneko S; Yakushijin Y; Nishimura Y; Inokuchi K; Miyakuni T; Nakao S; Kishi K; Kubonishi I; Dan K; Fujita S
Blood; 1998 Nov; 92(9):3355-61. PubMed ID: 9787173
[TBL] [Abstract][Full Text] [Related]
4. HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes.
Yasukawa M; Ohminami H; Kojima K; Hato T; Hasegawa A; Takahashi T; Hirai H; Fujita S
Blood; 2001 Sep; 98(5):1498-505. PubMed ID: 11520800
[TBL] [Abstract][Full Text] [Related]
5. BCR-ABL-specific CD4
Ueda N; Zhang R; Tatsumi M; Liu TY; Kitayama S; Yasui Y; Sugai S; Iwama T; Senju S; Okada S; Nakatsura T; Kuzushima K; Kiyoi H; Naoe T; Kaneko S; Uemura Y
Cell Mol Immunol; 2018 Jan; 15(1):15-26. PubMed ID: 27181332
[TBL] [Abstract][Full Text] [Related]
6. Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide.
Bosch GJ; Joosten AM; Kessler JH; Melief CJ; Leeksma OC
Blood; 1996 Nov; 88(9):3522-7. PubMed ID: 8896419
[TBL] [Abstract][Full Text] [Related]
7. A BCR-ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an Ii(b2a2) construct.
ten Bosch GJ; Kessler JH; Joosten AM; Bres-Vloemans AA; Geluk A; Godthelp BC; van Bergen J; Melief CJ; Leeksma OC
Blood; 1999 Aug; 94(3):1038-45. PubMed ID: 10419896
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia.
Nieda M; Nicol A; Kikuchi A; Kashiwase K; Taylor K; Suzuki K; Tadokoro K; Juji T
Blood; 1998 Feb; 91(3):977-83. PubMed ID: 9446659
[TBL] [Abstract][Full Text] [Related]
9. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes.
Buzyn A; Ostankovitch M; Zerbib A; Kemula M; Connan F; Varet B; Guillet JG; Choppin J
Eur J Immunol; 1997 Aug; 27(8):2066-72. PubMed ID: 9295046
[TBL] [Abstract][Full Text] [Related]
10. HLA-DR1-restricted bcr-abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates.
Mannering SI; McKenzie JL; Fearnley DB; Hart DN
Blood; 1997 Jul; 90(1):290-7. PubMed ID: 9207464
[TBL] [Abstract][Full Text] [Related]
11. Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients.
Osman Y; Takahashi M; Zheng Z; Koike T; Toba K; Liu A; Furukawa T; Aoki S; Aizawa Y
Leukemia; 1999 Feb; 13(2):166-74. PubMed ID: 10025889
[TBL] [Abstract][Full Text] [Related]
12. A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells.
Zorn E; Orsini E; Wu CJ; Stein B; Chillemi A; Canning C; Alyea EP; Soiffer RJ; Ritz J
Transplantation; 2001 Apr; 71(8):1131-7. PubMed ID: 11374415
[TBL] [Abstract][Full Text] [Related]
13. CTLs specific for bcr-abl joining region segment peptides fail to lyse leukemia cells expressing p210 bcr-abl protein.
Chen W; Qin H; Reese VA; Cheever MA
J Immunother; 1998 Jul; 21(4):257-68. PubMed ID: 9672847
[TBL] [Abstract][Full Text] [Related]
14. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.
Pinilla-Ibarz J; Cathcart K; Korontsvit T; Soignet S; Bocchia M; Caggiano J; Lai L; Jimenez J; Kolitz J; Scheinberg DA
Blood; 2000 Mar; 95(5):1781-7. PubMed ID: 10688838
[TBL] [Abstract][Full Text] [Related]
15. Specific human cellular immunity to bcr-abl oncogene-derived peptides.
Bocchia M; Korontsvit T; Xu Q; Mackinnon S; Yang SY; Sette A; Scheinberg DA
Blood; 1996 May; 87(9):3587-92. PubMed ID: 8611681
[TBL] [Abstract][Full Text] [Related]
16. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein.
Clark RE; Dodi IA; Hill SC; Lill JR; Aubert G; Macintyre AR; Rojas J; Bourdon A; Bonner PL; Wang L; Christmas SE; Travers PJ; Creaser CS; Rees RC; Madrigal JA
Blood; 2001 Nov; 98(10):2887-93. PubMed ID: 11698267
[TBL] [Abstract][Full Text] [Related]
17. b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia.
Norbury LC; Clark RE; Christmas SE
Br J Haematol; 2000 Jun; 109(3):616-21. PubMed ID: 10886212
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia.
Yotnda P; Firat H; Garcia-Pons F; Garcia Z; Gourru G; Vernant JP; Lemonnier FA; Leblond V; Langlade-Demoyen P
J Clin Invest; 1998 May; 101(10):2290-6. PubMed ID: 9593785
[TBL] [Abstract][Full Text] [Related]
19. Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes.
Makita M; Azuma T; Hamaguchi H; Niiya H; Kojima K; Fujita S; Tanimoto M; Harada M; Yasukawa M
Leukemia; 2002 Dec; 16(12):2400-7. PubMed ID: 12454745
[TBL] [Abstract][Full Text] [Related]
20. BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors.
Pawelec G; Max H; Halder T; Bruserud O; Merl A; da Silva P; Kalbacher H
Blood; 1996 Sep; 88(6):2118-24. PubMed ID: 8822931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
